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Abstract A liquid chromatography separation with electro-
spray ionisation and tandem mass spectrometry detection
method was developed for the simultaneous quantification
of ten commonly handled cytotoxic drugs in a hospital
pharmacy. These cytotoxic drugs are cytarabine, gemcita-
bine, methotrexate, etoposide phosphate, cyclophospha-
mide, ifosfamide, irinotecan, doxorubicin, epirubicin and
vincristine. The chromatographic separation was carried out
by RPLC in less than 21 min, applying a gradient elution of
water and acetonitrile in the presence of 0.1% formic acid.
MS/MS was performed on a triple quadrupole in selected
reaction monitoring mode. The analytical method was
validated to determine the limit of quantification (LOQ)
and quantitative performance: lowest LOQs were between
0.25 and 2 ng mL−1 for the ten investigated cytotoxic
drugs; trueness values (i.e. recovery) were between 85%
and 110%, and relative standard deviations for both
repeatability and intermediate precision were always infe-
rior to 15%. The multi-compound method was successfully
applied for the quality control of pharmaceutical formula-
tions and for analyses of spiked samples on potentially
contaminated surfaces.
Keywords Cytotoxic . Antineoplastic drugs . LC–MS/MS .
Pharmaceutical formulation . SRM . Validation
Introduction
During the last decades, the number of patients receiving
anticancer chemotherapy treatments based on cytotoxic
drugs has steadily increased. Simple analytical methods are
thus required in different pharmaceutical fields, such as
quality control or environmental monitoring. Different
methods have already been published such as simple flow
injection analysis and high-performance liquid chromatog-
raphy (HPLC)-UV/Vis assays for cytotoxic drugs by
Delmas et al. for quality control of cytotoxic preparations
in a centralised parenteral preparation unit [1] or simulta-
neous determination of three anthracycline drugs (doxoru-
bicin, daunorubicin and idarubicin) in serum samples by
capillary electrophoresis (CE) with laser-induced fluores-
cence by Pérez-Ruiz et al. for therapeutic drug monitoring
[2]. Due to their toxicity, the analysis of cytotoxic drugs is
also useful for environmental monitoring and control of
cytotoxic traces in wastewater. As an example, a CE-DAD
method for the quantification of 5-fluorouracil in wastewa-
ter of hospital effluents was published by Mahnik et al. [3].
Despite safety standards for handling cytotoxic agents, it
has been shown that health care professionals are still exposed
to these toxic compounds. For instance, several studies
reported low-level contamination of these compounds on
workbenches, floors, vials, gloves and isolators [4–12].
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Moreover, cytotoxic traces have been found in urine of health
care professionals [12–15]. Rapid, reliable and validated
analytical methods are thus needed for the safety of the
operator handling these hazardous drugs and to reduce the
exposure at the lowest possible level [16]. A review about
analytical methods used for biological and environmental
monitoring of hospital personnel exposed to antineoplastic
agents was published by Turci et al. [17]. Different
instrumental techniques were used depending on the studied
analyte. Most of the presented studies used a specific method
for the determination of a single cytotoxic drug. For
example, a very sensitive voltammetry for platinum drugs,
as well as GC–MS methods for the quantification of
cyclophosphamide, ifosfamide and fluorouracil, was devel-
oped by Schmaus et al. for environmental and biological
monitoring [18]. These methods presented very good
quantitative performance and detection limits (i.e. 0.1 to
1 pg per sample) and are thus ideal for establishing target
guideline values for cytotoxic contamination or for selecting
a single compound as a model marker for potential
contaminations. On the other hand, such methods are time
consuming and not very cost-effective to get an overview of
several cytotoxic contaminations. For the latter, multi-
compound methods are required. Different approaches have
gemcitabinecytarabine cyclophosphamide ifosfamide
methotrexate etoposide phosphate irinotecan
epirubicindoxorubicin vincristine
Fig. 1 Chemical structure of the ten studied cytotoxic drugs
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been developed using liquid chromatography–tandem mass
spectrometry (LC–MS/MS) for the simultaneous determination
of gemcitabine, taxol, cyclophosphamide and ifosfamide by
Sottani et al. [19] and for cyclophosphamide, methotrexate and
5-fluorouracil for surface contamination by Sabatini et al. [11].
However, to our knowledge, there is still a lack of simple
validated methods for the simultaneous determination of
different cytotoxic agents. For drug treatment monitoring or
quality control of pharmaceutical formulations, single-
compound strategies are often sufficient, but generic
multi-compound methods allow simplifying the control. In
addition, multi-compound methods are mandatory for
environmental analyses. The aim of this work was to
develop and validate a simple and sensitive LC–MS/MS
method for the simultaneous quantitative determination of
ten cytotoxic drugs contained in aqueous samples.
Experimental
Chemicals and reagents
The study was performed with the following commercially
available cytotoxic drugs (see Fig. 1 for their structure and
Table 1): Campto® (irinotecan, 20 mg mL−1) and Cytosar®
(cytarabine, 20 mg mL−1) were purchased from Pfizer AG
(Zürich, Switzerland), gemcitabine Teva® (gemcitabine
reconstituted in water at 20 mg mL−1) and vincristine
Teva® (vincristine 1 mg mL−1) from Teva Pharm AG
(Aesch, Switzerland), Holoxan® (ifosfamide reconstituted
in water at 40 mg mL−1) and Endoxan® (cyclophosphamide
reconstituted in glucose 5% at 20 mg mL−1) from Baxter
AG (Volketswil, Switzerland), methotrexate Farmos®
(methotrexate 2.5 mg mL−1) from Orion Pharma (Zug,
Switzerland), Etopophos® (etoposide phosphate reconsti-
tuted in water at 20 mg mL−1) from Bristol-Myers Squibb
SA (Baar, Switzerland), Doxorubine Ebewe® (doxorubicin
2 mg mL−1) from Ebewe Pharma (Cham, Switzerland) and
Epirubicin Actavis Solution® (epirubicin 2 mg mL−1) from
Actavis (Regensdorf, Switzerland).
The reconstitution of Etopophos, Gemcitabine Teva and
Holoxan was done with water for injectables, obtained from
Bichsel Laboratories (Interlaken, Switzerland); glucose 5% for
the reconstitution of Endoxan was from Sintetica-Bioren SA
(Couvet, Switzerland). The internal standard (IS) [13C, 2H3]-
methotrexate was purchased from Alsachim (Illkirch, France).
Equipment
Analyses were carried out with a high-performance liquid
chromatography system Accela from Thermo Fisher Scien-
Table 1 Preparation of cytotoxic stock solutions
Brand name Manufacturer Drug Drug concentration
(mg mL−1)
S1 (20 μg mL−1) (in
100 mL H2O)
Vincristine Teva® Teva (Aesch, Switzerland) Vincristine 1 2.000 mL
Doxorubicin Ebewe® Ebewe Pharma Schweiz (Cham,
Switzerland)
Doxorubicin 2 1.000 mL
Epirubicin Actavis
Solution®
Actavis (Regensdorf, Switzerland) Epirubicin 2 1.000 mL
Methotrexate Farmos® Orion Pharma (Zug, Switzerland) Methotrexate 2.5 0.800 mL
Endoxan® Baxter AG (Volketswil,
Switzerland)
Cyclophosphamide 20 0.100 mL
Cytosar® Pfizer AG (Zürich, Switzerland) Cytarabine 20 0.100 mL
Etopophos® Bristol-Myers Squibb SA (Baar,
Switzerland)
Etoposide
phosphate
20 0.100 mL
Gemcitabine Teva® Teva (Aesch, Switzerland) Gemcitabine 20 0.100 mL
Campto® Pfizer AG (Zürich, Switzerland) Irinotecan 20 0.100 mL
Holoxan® Baxter AG (Volketswil,
Switzerland)
Ifosfamide 40 0.050 mL
Table 2 Gradient elution programme
Time [min] Solvent A (%) Solvent B (%) Solvent C [%]
0 88 2 10
2.0 88 2 10
2.5 69 21 10
10 69 21 10
13 60 30 10
13.5 40 50 10
15.5 40 50 10
16 88 2 10
21 88 2 10
Mobile phase: A water, B acetonitrile, C formic acid 1%
Flow rate of 200 μL min−1
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tific Inc. (Waltham, MA) consisting of a quaternary pump
equipped with an online degasser, an auto-sampler and a
solvent platform. The chromatographic system was coupled
to a triple quadrupole Quantum Discovery MS from
Thermo Fisher Scientific equipped with an ion max
electrospray ionisation (ESI) interface and operated with
Xcalibur software (Thermo Fisher Scientific).
Separations were done on a ZORBAX SB-C18 RR 2.1×
100 mm 3.5-μm column from Agilent Technologies
(Waldbronn, Germany).
Solutions
Mobile-phase solutions
Chromatography was performed using Lichrosolv® HPLC-
grade acetonitrile (ACN) and ultrapure water from Merck
(Darmstadt, Germany) and formic acid (FA) 99% from
Biosolve (Valkenswaard, the Netherlands). The mobile
phase constituted of three solutions: ultrapure water
(solution A), ACN (solution B) and FA 1% (solution C).
Table 3 Instrument method for the LC–MS/MS analysis for ten cytotoxic drugs with [13C, 2H3]-methotrexate as internal standard
Time segment (min) Scan event Drug Parent (m/z) Product (m/z) CE (eV) Mean RT (min)
0–2.2 1 Cytarabine 244.0 112.3 15 1.9
2.2–4 2 Gemcitabine 264.7 112.3 20 2.6
4–7 3 Methotrexate 455.2 308.0 20 6.0
4 [13C, 2H3] methotrexate 459.2 312.2 20 6.0
7–10 5 Etoposide phosphate 691.0 691.0 15 7.5
10–13 6 Ifosfamide 261.1 92.3, 140.2 20 11.4
154.1, 232.9
Cyclophosphamide 261.1 92.3; 140.2 20 12.2
154.1, 232.9
13–14 7 Irinotecan 587.9 587.3 20 13.7
14–21 8 Doxorubicin 544.6 379.2, 397.1 15 14.8
Epirubicin 544.6 379.2, 397.1 15 15.3
9 Vincristine 413.3 353.2 30 15.2
Fludarabine
Bortezomib
Vincristine
Azacitidine
Ifosfamide
Selected drugs
Mitomycine Not analyzed
Docetaxel
Oxaliplatine
Methotrexate
Paclitaxel
Epirubicin
Cytarabine
Doxorubicin
Irinotecan
Carboplatine
Gemcitabine
Etoposide phosphate
Cyclophosphamide
Cisplatine
Fluorouracil
0 200 400 600 800 1000 1200 1400
Number of preparation per year
Fig. 2 Overview of the 20 most
prepared cytotoxic drugs at the
pharmacy of Geneva University
Hospitals in 2009. Black back-
grounds represent the selected
compounds
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New solvents were prepared for each series of analysis.
Washing of the needle and the injection loop was performed
with 5% ACN in water after each injection.
Cytotoxic stock solutions, calibration standards, validation
standards and internal standard
The operator prepared all solutions (i.e. drug reconstitutions
and sample dilution) in appropriate conditions for handling
hazardous compounds as cytotoxic agents. Moreover, the
development of the method was performed with drug
specialities to avoid direct contact of the operator to
cytotoxic powder and to minimise contamination risk by
preparing working solutions.
A main stock solution (S1) containing the ten cytotoxic
drugs was prepared by diluting each compound in water at a
concentration of 20 μg mL−1 (see Table 1). This solution was
further diluted to obtain two independent intermediate stock
solutions: S2 at 2 μg mL−1 and S3 at 200 ng mL−1 in FA
0.1%. The calibration standards and validation standards
were prepared by diluting S2 and S3 to 12 concentration
levels in FA 0.1% (0.25–200 ng mL−1). All samples were
immediately stored at 15 °C in the LC auto-sampler and
analysed within the day.
Aliquots of the IS, [13C, 2H3]-methotrexate, were
prepared with a mixture of ACN and water (75:25v/v) at
250 μg mL−1 and stored at −22°C for 6 months. No sample
degradation could be observed. Stock solutions of IS were
regularly diluted at 1 μg mL−1 in water, and they were
stable for at least 2 weeks at 2–8 °C.
LC–MS/MS conditions
The mobile-phase flow rate was set at 200 μL min−1 using
the gradient elution programme described in Table 2. The
thermostated auto-sampler was maintained at 15 °C, and
the injection volume was 25 μL.
Positive ESI conditions were capillary temperature set at
325 °C, spray voltage at 4 kV and sheath and auxiliary gas
(nitrogen) flow rate at 45 and 2 psi, respectively. MS/MS
was acquired in selected reaction monitoring (SRM) mode
in Q1 and Q3. The Q2 collision gas (argon) pressure was
set at 1.5 mTorr. Determination of Q2 potential settings and
MS/MS transitions (Q1 and Q3) was carried out by direct
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Fig. 3 LC–MS/MS chromato-
gram of a sample containing
ten cytotoxic drugs and the
internal standard at 50 ng mL−1.
Column: ZORBAX SB-C18 RR
2.1×100 mm 3.5 μm; flow rate
200 μL min−1; gradient condi-
tions and scan events are
reported in Tables 2 and 3,
respectively
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infusion of each cytotoxic drug solution at a concentration
of 1 μg mL−1 diluted in 50:50 of water/methanol with 0.1%
FA. Selected m/z transitions and collision energy for each
analyte are reported in Table 3. Seven segments with nine
scan events of data acquisition were programmed in the
positive mode during the entire analytical run (Table 3).
Chromatographic data acquisition, peak integration and
quantification were performed using the Xcalibur software
(ThermoQuest, San Jose, CA, USA).
Method validation
Method validation was performed to estimate quantitative
performance of the analytical method. The validation was
carried out over three series: each series involved (1)
freshly prepared calibration, validation samples and
solvents, (2) washing of the column and LC system, (3)
LC shutoff, (4) cleaning the capillary and cone of the MS
with water and methanol and (5) tuning/calibration of the
MS system. Calculations were performed using area ratios
of the ten cytotoxic drugs on the IS ([13C, 2H3]-
methotrexate). There were two independent sample prep-
arations (calibration and validation samples) at 12 con-
centration levels (0.25–200 ng mL−1) with injections in
triplicate.
Application to cytotoxic formulations and environmental
samples
For quality control, cytotoxic drugs were determined in
formulations prepared at the Geneva University Hospitals
pharmacy. Therefore, formulations were diluted in 0.1% FA
to obtain a final concentration of 200 ng mL−1 with
50 ng mL−1 of the IS.
For environmental applications, a standard solution of
the ten cytotoxic drugs was spiked over a polypropylene
infusion bag (NaCl 0.9% 50 mL) and over a stainless steel
surface (100 cm2) to obtain a concentration of 2.5 ng cm−2.
The spiked area was wiped with a blotting paper (Whatman
903®) and an aqueous solution of IS was added. Then,
drugs were extracted from the paper in 5 mL of FA 0.1% in
glass vials by ultrasonication for 15 min. The procedure
was repeated in triplicate (N=3) for each surface.
Results and discussion
Method development
Selection of the cytotoxic agents and internal standard
The developed LC–MS/MS method allows the determination
of ten cytotoxic drugs, namely cytarabine, gemcitabine,Ta
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methotrexate, etoposide phosphate, cyclophosphamide, ifos-
famide, irinotecan, doxorubicin, epirubicin and vincristine.
These ten compounds were selected among the 20 most
prepared cytotoxic drugs at the pharmacy of the Geneva
University Hospitals (Fig. 2). The selection was a compro-
mise between the most prescribed drugs and their toxicity
and analytical considerations. For example, 5-fluorouracil,
which is the most prepared chemotherapy drug in 2008, was
not included because it is not classified as a carcinogen for
humans [20], and a contamination of this compound is less
hazardous for exposed personal. Furthermore, 5-fluorouracil
is a very polar compound poorly retained in our analytical
conditions. Three platinum compounds (i.e., cisplatin,
carboplatin and oxaliplatin) presented a high percentage of
prescribed chemotherapies and belong to the most toxic
compounds, but they need other detection techniques such as
ICP–MS or voltammetry [17, 18, 21, 22] and were thus not
included in this study. Finally, the ten selected drugs belong
to different cytotoxic families with different toxicities, giving
an excellent overview of possible contamination.
In order to exclude a cross contamination of the IS, a
deuterated compound was chosen: [13C, 2H3]-methotrexate
was used as IS as it exhibited high ESI–MS/MS response
and was eluted in the middle retention time window of the
ten investigated cytotoxic drugs.
Optimisation of LC–ESI–MS/MS conditions
The described method enables the quantification of ten
cytotoxic compounds with a mobile-phase composition of
water, acetonitrile and 0.1% formic acid. With the selected
gradient (Table 2), vincristine and epirubicin were the only
unresolved cytotoxic drugs but presented different scan events
in SRM mode. All other compounds were separated in less
than 16 min (21 min including the column reconditioning). A
typical chromatogram, obtained from the analysis of a
calibration sample with 50 ng mL−1 of each analyte and
50 ng mL−1 of IS in FA 0.1%, is shown in Fig. 3.
ESI–MS/MS conditions were optimised for each analyte,
and the best compromise for all compounds was chosen.
All drugs were analysed in positive mode. Different values
for capillary temperature, spray voltage, sheath and auxil-
iary gas were tested (data not shown). Response signals of
compounds increased with capillary temperature, but
cytarabine gemcitabine30% 30%
0% 0%
30% 30%
0 50 100 150 200 0 50 100 150 200
methotrexate etoposide phosphate30% 30%
0% 0%
30% 30%
0 50 100 150 200 0 50 100 150 200
ifosfamide cyclophosphamide
30% 30%
0% 0%
30% 30%
B
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Fig. 4 Accuracy profile for the
quantification of ten cytotoxic
drugs by LC–MS/MS in the
concentration range from 1 to
200 ng mL−1, calculated from
the trueness and intermediate
precision reported in Table 4;
dashed lines represent the ac-
ceptance limits of ±30%
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doxorubicin and epirubicin were degraded at temperatures
above 325 °C. Final optimised conditions were obtained
with a spray voltage of 4 kV, a capillary temperature at
325°C, sheath gas at 45 psi and auxiliary gas at 2 psi. The
m/z transitions and collision energy for each analyte were
successfully determined and reported in Table 3.
Triple quadrupole instruments provide excellent sensi-
tivity and selectivity in SRM. Additionally, the MS/MS
method can be segmented into various time windows
containing different SRM events to increase the signal-to-
noise ratio. Thus, seven time segments with nine scan
events of data acquisition were used during the entire
analytical run. This approach is particularly useful in
environmental monitoring because of the relatively low
concentration of each individual analyte. With the presented
method, cytarabine, gemcitabine, etoposide phosphate and
irinotecan were detected in their own time segment with a
specific scan event. Doxorubicin and epirubicin, as cyclo-
phosphamide and ifosfamide, were analysed with the same
scan event in the same segment, but they were well
separated by LC. Vincristine was detected in the same
segment as doxorubicin and epirubicin, but with another
scan event. Therefore, all cytotoxic drugs could be
quantified in satisfied analytical conditions.
Method validation
The method was validated with calibration and validation
samples in 0.1% formic acid. Quantitative performance was
estimated in three separate series at 12 concentration levels,
with three repetitions for calibration standard and three
repetitions for validation standard. As a result, 72 injections
were carried out per series, for a total of 216 analyses.
Calibration model and concentration range
From all calibration standards, different regression models
were tested to determine the best response function for the
ten cytotoxic drugs: a weighted linear regression model
with a weight equal to 1/x gave the best quantitative
performance in the studied concentration range with a
determination coefficient (r2) of about 0.999 and superior to
0.996 for all tested compounds (Table 4).
The limit of detection was set at a signal-to-noise ratio of
3:1. LODswere significantly below 1 ngmL−1 for all cytotoxic
drugs (Table 4). The lowest limit of quantification (LOQ) was
determined to ensure relative standard deviation (RSD)
inferior to 15%. Lowest LOQs were determined between
0.25 and 2 ng mL−1 for all cytotoxic drugs (Table 4). The
upper LOQ was set at 200 ng mL−1 for all cytotoxic drugs.
Higher LOQ values could theoretically be used, but in order
to avoid unnecessary exposure of the operator to the cytotoxic
agents, concentrations above 200 ng mL−1 were not analysed.Ta
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Due to practical considerations, the concentration range for all
cytotoxic drugs was limited from 1 to 200 ng mL−1.
Accuracy, trueness and precision
Concentrations of validation standards were calculated from
the calibration model. Trueness was expressed in percent as
the ratio between theoretical and average measured values
at each concentration level. Trueness values were between
85% and 110%, as reported in Table 4.
Repeatability and intermediate precision were expressed
as RSD of the ratio of the intra-day standard deviation (sr)
and between-day standard deviation (sR), respectively. The
sr and sR values were obtained using ANOVA analyses.
RSD values below 15% were obtained for each compound
(Table 4).
To visualise the overall method variability, the accuracy
profile of each cytotoxic drug was built from 1 to
200 ng mL−1, combining trueness and intermediate preci-
sion as the confidence interval [23]. As presented in Fig. 4,
the total error did not exceed ±30% for all compounds in
their quantification concentration range. Only doxorubicin
and epirubicin presented a superior limit at 1 ng mL−1
outside the tolerance of 30%, further justifying the selected
LOQ of 2 ng mL−1 for these two compounds (“Calibration
model and concentration range”).
Consequently, the developed LC–ESI–MS/MS method
presents quantitative performance fully compatible with
environmental monitoring of cytotoxic drugs on surfaces or
in combination with a sample preparation for biological
sample analyses. Alternatively, the method can be used for
quality control or stability studies of pharmaceutical
formulations due to the very satisfactory performance at
200 ng mL−1 with a total error inferior to 5%.
Applications
In order to demonstrate the applicability of the LC–ESI–MS/
MS method to real samples, determination of the ten cytotoxic
agents was achieved in pharmaceutical formulations for quality
control and in wiping samples for environmental monitoring.
Concentrations of the cytotoxic agents were calculated with
reference to a calibration curve constructed the same day with
five levels of calibration standard (1, 2, 10, 50 and
200 ng mL−1) containing the ten drugs and weighted linear
regression with a weight equal to 1/x for each compound.
For quality control, pharmaceutical formulations were
analysed by diluting the samples to a target value of
200 ng mL−1. As shown in Table 5, concentrations of the
tested pharmaceutical formulations were found to be ±10%
(including both trueness and precision) of the prescribed
concentration which corresponds to the acceptance limit for
preparations of the HUG pharmacy.
The method was also successfully applied to environ-
mental samples. The recovery rate was determined for each
cytotoxic compound according to the surface type (see
Table 5).
Conclusions
A simple LC–ESI–MS/MS method was successfully devel-
oped for the simultaneous quantification of ten cytotoxic
drugs (cytarabine, gemcitabine, methotrexate, etoposide
phosphate, cyclophosphamide, ifosfamide, irinotecan,
doxorubicin, epirubicin and vincristine) in 21 min, gradient
equilibration time included. This method was validated and
exhibited satisfactory quantitative performance in terms of
limit of quantification, domain range, trueness and preci-
sion: the accuracy profile showed total errors inferior to
±30% for all compounds in their quantification domain
range, from 1 or 2 ng mL−1 up to 200 ng mL−1, and total
errors inferior to ±5% at 200 ng mL−1. Therefore, the
method can be used for different applications, as shown by
its successful utilisation for quality control of pharmaceu-
tical formulations and environmental monitoring.
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